MedTrace Logo

Special Investigation in Patients With Ulcerative Colitis

NCT01947816 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1621

Last updated 2019-05-13

Study results available
· View outcomes & findings →

Summary

This investigation will be conducted to obtain the following information regarding the use of Humira 40 mg Syringe 0.8 mL for Subcutaneous Injection in patients with Ulcerative Colitis.

1. Unknown adverse reactions (in particular, clinically significant)
2. Incidence and conditions of occurrence of adverse reactions in clinical practice
3. Factors likely to affect the safety and effectiveness

Conditions

Sponsors & Collaborators

Principal Investigators

  • AbbVie Inc. · AbbVie

Eligibility

Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-09
Primary Completion
2018-02-15
Completion
2018-02-15

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01947816 on ClinicalTrials.gov